What is EMTALA and how does it relate to abortion care?

The Emergency Medical Treatment and Labor Act (EMTALA) requires hospitals receiving Medicare funds to provide treatment for emergency medical conditions, which includes certain abortion-related emergencies. SMFM provides guidance and advocacy to clarify EMTALA’s role in abortion care.

What legal challenges affect access to medication abortion?

Several ongoing court cases are challenging access to mifepristone, a key medication for abortion care. SMFM tracks these developments, advocates for evidence-based policies, and provides clinical resources for MFMs navigating these restrictions.

What should clinicians know about over-the-counter oral contraceptives?

In July 2023, the FDA approved Opill (norgestrel) for nonprescription use. Clinicians should be aware of its safety profile, expected insurance coverage issues, and anticipated availability to help counsel patients effectively.

How can MFMs stay updated on reproductive health policy and clinical guidance?

MFMs can subscribe to SMFM’s Reproductive Health Updates Newsletter for the latest advocacy updates, clinical guidance, and educational opportunities related to reproductive healthcare.

Reproductive Health Updates and Resources for MFMs

The reproductive health landscape is evolving quickly, with new laws, policies, and clinical challenges that impact maternal-fetal medicine (MFM) practice. This page provides up-to-date resources, advocacy updates, and educational materials to help MFM specialists stay informed and deliver safe, equitable care. Explore the latest developments on EMTALA and abortion care, medication abortion, and over-the-counter oral contraceptives, as well as SMFM’s role in shaping policy and clinical guidance.

Medical Emergencies and Access to Abortion Care: Federal law requires hospitals that receive Medicare funds to treat anyone presenting with an emergency medical condition. Access the 2023 guidance from the U.S. Department of Health and Human Services and learn about SMFM’s expert input in related court filings.

Medication Abortion: High-profile legal cases continue to shape access to mifepristone. Learn more about SMFM’s advocacy efforts, clinical guidance, and educational tools for clinicians providing medication abortion.

Over-the-Counter Oral Contraceptives: In July 2023, the FDA approved the nonprescription sale of Opill (norgestrel). Access information on product safety, insurance coverage, and expected availability.

Reproductive Health Updates Newsletter: Stay current on reproductive health developments, advocacy, and clinical guidance with SMFM’s regular newsletter.